论文部分内容阅读
目的:探讨贝伐单抗作为抗血管内表皮生长因子受体(VEGFR)通路药物应用于晚期非鳞非小细胞肺癌(NSNSCLC)的临床价值。方法:抽取2018年1月至2020年2月在山西省肿瘤医院治疗的128例NSNSCLC患者(Ⅳ期)，将其分为两组。观察组64例，应用培美曲塞＋顺铂＋贝伐单抗治疗；对照组64例，应用培美曲塞＋顺铂治疗。比较两组患者的近期疗效、生存时间及不良反应情况。结果:观察组患者客观缓解率为53.13%，临床获益率为79.69%，对照组患者分别为26.65%、62.50%，差异有统计学意义(n P<0.05)；截至末次随访，观察组患者的中位生存期为13个月，对照组为9个月，差异有统计学意义(n P<0.05)；化疗期间，观察组患者高血压发生率为26.56%，对照组为1.56%，差异有统计学意义(n P0.05)。n 结论:对晚期NSNSCLC患者应用抗VEGFR通路药物贝伐单抗治疗可提高近期疗效，延长患者生存时间，且患者耐受性较好，但应注意预防高血压。“,”Objective:To investigate the therapeutic value of bevacizumab as an anti vascular epidermal growth factor receptor (VEGFR) pathway drug in the treatment of advanced non squamous non-small cell lung cancer (NSCLC).Methods:A total of 128 NNSSCLC patients (stage IV) who were treated in Shanxi Cancer Hospital from January 2018 to February 2020 and were divide into two groups. Sixty-four cases in the observation group were treated with pemetrexed + cisplatin + bevacizumab; 64 cases in the control group were treated with pemetrexed + cisplatin. The short-term efficacy, survival time and toxicity of the two groups of patients were compared.Results:The objective remission rate and clinical benefit rate of the observation group were 53.13% and 79.69%, respectively, while those of the control group were 26.65% and 62.50%, the difference was statisicolly significant (n P<0.05); up to the last follow-up, the median survival time of the observation group was 13 months, and that of the control group was 9 months, the difference was statistically significant(n P<0.05); during chemotherapy, the incidence of hypertension in the observation group was 26.56%, and that in the control group was 1.56%, the difference was statistically significant (n P0.05).n Conclusions:In patients with advanced NSNSCLC, the application of the anti VEGFR pathway drug bevacizumab can improve the short-term effects, prolong the survival time of patients, and the patient's tolerance is better, but we should pay attention to prevent hypertension.